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Abstract
Background: Australia has a comparatively high incidence of colorectal (bowel) cancer; however, population
screening uptake using faecal occult blood test (FOBT) remains low. This study will determine the impact on
screening participation of a novel, Internet-based Personalised Decision Support (PDS) package. The PDS is
designed to measure attitudes and cognitive concerns and provide people with individually tailored information, in
real time, that will assist them with making a decision to screen. The hypothesis is that exposure to (tailored) PDS
will result in greater participation in screening than participation following exposure to non-tailored PDS or
resulting from the current non-tailored, paper-based approach.
Methods/design: A randomised parallel trial comprising three arms will be conducted. Men and women aged
50-74 years (N = 3240) will be recruited. They must have access to the Internet; have not had an FOBT within the
previous 12 months, or sigmoidoscopy or colonoscopy within the previous 5 years; have had no clinical diagnosis
of bowel cancer. Groups 1 and 2 (PDS arms) will access a website and complete a baseline survey measuring
decision-to-screen stage, attitudes and cognitive concerns and will receive immediate feedback; Group 1 will
receive information ‘tailored’ to their responses in the baseline survey and group 2 will received ‘non-tailored’
bowel cancer information. Respondents in both groups will subsequently receive an FOBT kit. Group 3 (usual
practice arm) will complete a paper-based version of the baseline survey and respondents will subsequently
receive ‘non-tailored’ paper-based bowel cancer information with accompanying FOBT kit. Following despatch of
FOBTs, all respondents will be requested to complete an endpoint survey. Main outcome measures are (1)
completion of FOBT and (2) change in decision-to-screen stage. Secondary outcomes include satisfaction with
decision and change in attitudinal scores from baseline to endpoint. Analyses will be performed using Chi-square
tests, analysis of variance and log binomial generalized linear models as appropriate.
Discussion: It is necessary to restrict participants to Internet users to provide an appropriately controlled evaluation
of PDS. Once efficacy of the approach has been established, it will be important to evaluate effectiveness in the
wider at-risk population, and to identify barriers to its implementation in those settings.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12610000095066
Background
In Australia, the risk of being diagnosed with colorectal
cancer (CRC) by the age of 85 years is 1 in 10 for males
and 1 in 14 for females, with the risk increasing sharply
from the age of 45 years [1]. In 2006, CRC accounted
for 10% of all invasive cancer-related deaths, second
only to lung cancer [2]. Despite evidence from rando-
mised clinical trials that both biennial and annual
screening using faecal occult blood testing reduces CRC
mortality [3-5] and incidence [6], the participation rate
remains low. Since 2007 the Australian government-
funded National Bowel Cancer Screening Program
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turning 50, 55 and 65 years with a free Faecal Occult
B l o o dT e s t( F O B T )k i t .T h i sh o m e - b a s e dt e s ti n v o l v e s
sending a stool sample to a laboratory to be analysed
for occult blood, ideally followed by colonoscopy for
those with a positive result. The 2008 participation rate
was 39% of the eligible population [1], with uptake vary-
ing between sexes (42% for females compared to 36%
for males). These suboptimal rates highlight the public
health challenge to optimise participation rates using
publicly delivered rather than clinician-based
interventions.
An understanding of the variables that encourage peo-
ple to participate in CRC screening using FOBT is
important for a number of reasons. Participation rate is
the critical determinant of population efficacy of screen-
ing as it improves outcomes independent of screening
technology. Early detection and treatment of precancer-
ous lesions and adenomas results in a significantly
higher survival rate than if treatment is delayed until
physical symptoms of the conditions are evident [4].
Moreover, the cost effectiveness of FOBT screening is
expected to increase as greater participation and earlier
detection of CRC reduces treatment costs and improves
longer-term survival rates [7].
Poor participation in screening can be attributed to
several factors including a poor understanding of cancer
and cancer risk [8], insufficient knowledge of CRC and
the value of screening [9,10] and a perception of the
screening process as distasteful or embarrassing [11,12].
Decision aids have been developed to overcome some of
the problems associated with poor participation in can-
cer prevention programs including participation in CRC
screening. Their purpose is to assist the decision making
of people facing health treatments or screening decisions
through increasing knowledge of and awareness about
personal risk and response alternatives. Screening aids
have been shown to improve knowledge, reduce decisio-
nal conflict and stimulate individuals to be more active
in decision making without increasing their anxiety
[13,14]. Furthermore, a meta-analysis of the effectiveness
of these aids confirms their utility for improving knowl-
edge of cancer screening by comparison to usual prac-
tice [15]. The utility of these aids is likely to be affected
by several factors including the theoretical framework
underpinning the aid, the format of the decision aid and
the nature and presentation of the information.
Theoretical framework
Two classes of behavioural theory hold particular rele-
vance to the development of decision aids designed to
enhance screening participation. These are described as
“continuum” and “stage” theories [16]. Continuum the-
ories focus on the exploration of psychosocial predictors
of intention to screen; a recent variant, the Preventive
Health Model (PHM), draws from other theoretical
models including the Health Belief Model [17]. The
PHM indicates that individual differences in prepared-
ness to screen for CRC can be attributed to scores on
five factors: salience and coherence (the extent to which
performing CRC screening is consistent with beliefs
about how to protect and maintain health); cancer wor-
ries (concerns about the consequences of CRC);
response efficacy (beliefs that undertaking CRC screen-
ing will be effective in reducing disease threat); social
influence (beliefs about, and desire to comply with the
attitudes of key others to CRC screening); and perceived
susceptibility (subjective personal risk for developing
CRC). These constructs have been validated in the U.S.
[18,19] and Australia [20]. It has been argued that the
PHM is enhanced when utilised with a “stage” theory
such as the Precaution Adoption Process Model
(PAPM) [21] which deconstructs behavioural intention
and posits that individuals are more likely to respond to
interventions aimed at their stage of readiness to engage
in screening. The PAPM describes people as being at
one of seven stages: unaware of the issue, heard of the
issue but unconcerned, considering action, decided
against a behaviour, decided to act, acting and lastly,
maintaining the behaviour over time. Myers and collea-
gues have demonstrated that groups of people at a spe-
cific stage of thinking about colorectal cancer screening
can be distinguished from people at a higher level in
terms of their responses to the variables included in the
PHM [22]. For example, for those people who have
“never heard of” FOBT (unaware of the issue), messages
which emphasise the PHM factors of salience and
coherence and perceived susceptibility are more likely to
move them toward a decision to screen, whereas mes-
sages focussing on perceived susceptibility and self effi-
cacy are more likely to resonate with those who have
“decided against” screening and encourage them toward
screening.
CRC screening decision aid format and the presentation
of information
T h eP A P Ma n dP H Mm o d e l sp r o v i d et h eb a s i su p o n
which to develop an understanding of the cognitive
frame of reference that underlies an individual’sd e c i -
sion-making around CRC screening. Research suggests
that the effectiveness of decision aids is enhanced when
the information provided is tailored to the needs of the
individual; the communications are consistently better
remembered and perceived as being more relevant than
non-tailored materials [23]. Tailoring messages accord-
ing to current decision stage (PAPM), and current
responses on the full range of psychosocial drivers mea-
sured in models like the PHM, should enhance
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decision, and minimise any feelings of anxiety or disso-
nance (“decisional conflict”).
Paper-based delivery of tailored messages has
improved screening uptake [24] but the feasibility of this
approach, if implemented on a large scale, has yet to be
established. A meta-analysis comparing web-based and
non-web-based informational interventions showed
enhanced outcomes among individuals using web-based
interventions, particularly in the areas of knowledge and
targeted behaviour change [25]. The potential advan-
tages of web-based delivery over traditional paper meth-
ods include the ability to present information to the
reader in a way that is more easily navigable than on
paper; the capacity to use context to enhance relevance
through the process of tailoring on key variables; and
the ability to provide instantaneous enactment of the
decision reached, thereby avoiding the difficulties that
are attached to procrastination (for example, screening
tests could be ordered instantly online or an appoint-
ment made with a doctor via email). Thus, there is a
need to test whether electronic delivery can achieve
similar or improved uptake rates compared to paper-
based delivery, particularly within a community setting.
A functional Internet-based Personalised Decision
Support system (PDS) developed by the Commonwealth
Scientific and Industrial Research Organisation (CSIRO)
Preventative Health Flagship is available for this study.
It is an interactive application that collects user informa-
tion in real-time and delivers instantaneous, persona-
lised messages aimed at moving individuals through the
decision stages relevant to CRC screening. An extensive
User Model drives a series of algorithms that underlie
an educational message library. These algorithms have
been developed to ensure that messages delivered to an
individual are united with natural language so that they
can be read in a coherent, logical manner. After log-in,
individuals complete a questionnaire that incorporates
PAPM and PHM variables. Items are rated on a 5-point
Likert scale from ‘strongly disagree’ to ‘strongly agree’.
The computer program processes these data to deter-
mine the individualised content to be delivered follow-
ing completion of the questionnaire. The resulting web
interface consists of tailored, personalised messages that
address relevant knowledge deficits and reinforce per-
ceptions when favourable to screening, or motivate peo-
ple to change perceptions when unfavourable. For
example, a library of messages has been created to
address response efficacy, a factor which relates strongly
to those who are “not considering” FOBT screening.
The response efficacy statement reads: “When colorectal
polyps are found and removed, colorectal cancer can be
prevented”. Participants who respond “disagree” receive
a personalised ‘motivating’ message reading;
“[Participant’s name], you don’t believe that colon cancer
screening is effective. In fact, it’s very effective ...“ Partici-
pants who respond ‘"agree” would receive a ‘reinforcing’
message: “You’ve told us that you believe colon cancer
screening is effective. You’re right ...“ Messages are also
presented in a specific order so that messages relating
to PHM factors which are most strongly associated with
an individual’s current decision stage [22] are presented
first with the aim of moving people through stages of
screening awareness and pre-screening contemplation to
a decision to participate.
In conclusion, communicating the necessity for CRC
screening and the effectiveness of screening tests avail-
able to the target population is a clearly demonstrated
need. Tailored decision support, delivered via the Inter-
net, holds the prospect of improving participation rates
and thereby health outcomes into the future.
Methods/Design
Study Aims
The primary aims of the study are to test whether (1) an
Internet-based, Personalised Decision Support package
(PDS) that delivers personalised information, tailored
according to preventive health variables and current
decision stage for screening enhances FOBT participa-
tion when compared to a non-tailored PDS package and
the current paper-based approach; and (2) whether tai-
lored PDS moves individuals to a higher decision stage
for screening compared with the other interventions.
Study design and setting
This study is a parallel group, randomised trial where a
randomly-selected, national sample of 3240 men and
w o m e na g e d5 0t o7 4y e a r sw h oa r ek n o w nt oh a v e
Internet access are randomised to a tailored or non-tai-
lored PDS, or a non-tailored, paper-based approach
(usual practice). Only one member from each household
will be recruited to avoid cross-contamination of the
groups. The trial design flowchart, with estimated attri-
tion rates, is shown in Figure 1.
Ethical considerations
Full ethical approval has been obtained from the CSIRO
Human Research Ethics Committee.
Identification of eligible participants
We will approach a randomly selected, national main-
land Australian sample of N = 18,000 urban dwelling,
m e na n dw o m e na g e d5 0 - 7 4y e a r si d e n t i f i e df r o mt h e
electoral roll. The sample will be stratified according
to population density at the Australian State level.
Rural areas and Tasmania will not be included because
the former will have added constraints associated with
potential difficulties in accessing gastroenterological
services and the latter has a population too small to
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pants will be approached via a posted Eligibility Ques-
tionnaire (EQ) and information sheet outlining the
nature and requirements of the study and asking them
to address the inclusion and exclusion criteria if they
are interested in participating. A pre-paid return envel-
ope will be enclosed for return of the documents.
There will be an opportunity for people to opt out at
this stage.
Determining eligibility for the study
Potential participants will be selected from those who
return the EQ and who are eligible based on criteria
shown in Additional File 1.
Randomisation
Those who have indicated, by return of the completed
EQ, that they have read the study information, are eligi-
ble and willing to participate in the study will be ran-
domly assigned to one of three arms (Figure 1). Block
randomisation using random block size will be utilised,
and stratification will be performed to ensure that the
numbers of participants receiving each intervention are
closely balanced within each Australian State.
Blinding
Data collectors for the primary outcome (FOBT uptake)
will be blinded to treatment arm allocation following
randomisation. Data analysts will be blinded to treat-
ment arm allocation and will become unblinded follow-
ing analysis of the primary outcomes. Participants and
investigators will not be blinded.
Study interventions
The study involves three arms: (1) CRC information and
invitation to screen via Internet access to ‘tailored’ PDS;
(2) CRC information and invitation to screen via Inter-
net access to ‘non-tailored’ PDS; and (3) paper-based
delivery of CRC information and invitation to screen,
consistent with usual practice in the National Bowel
Cancer Screening Program (NBCSP). Interventions spe-
cific to each arm and study stage are shown in Table 1
and described below. All groups will receive a second
Figure 1 Trial design flow chart and estimated attrition rates.
Table 1 Study interventions by phase and arm
Eligibility Phase 1 Arm Intervention Phase
2.1
Intervention Phase 2.2 Evaluation
Phase 3.1
Evaluation
Phase 3.2
Information Sheet + Eligibility
Questionnaire (EQ) then eligible
participants randomised to study Arm
Internet-based
Tailored PDS
Information Sheet
Baseline survey (BS)
Receipt of tailored
messages
Electronic version of
NBCSP consumer
information booklet
FOBT kit received
Reminder to revisit tailored
messages and consumer
information booklet
Endpoint
survey (ES)
Telephone
qualitative
interview
(subset)
Internet-based
non-tailored
PDS
Information Sheet
Baseline Survey
Electronic version of
NBCSP consumer
information booklet
FOBT kit received
Reminder to revisit consumer
information booklet
Endpoint
survey
Telephone
qualitative
interview
(subset)
Paper-based
non-tailored
(usual practice)
Information Sheet
Baseline Survey
FOBT kit received
Printed version of NBCSP
consumer information
booklet
Endpoint
survey
Telephone
qualitative
interview
(subset)
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again to opt out at this stage.
Participants in each of the two PDS arms will be
required to access the PDS web site and log in with a
unique user name and ID provided by the researchers.
Once logged on, participants in both arms will complete
a Baseline Survey (BS) that will collect demographic
data, PAPM decision stage and measure PHM variables.
Participants in the Tailored PDS arm will receive appro-
priately motivating or reinforcing messages tailored to
their responses to the BS variables. In addition they will
be able to access an electronic version of the NBCSP’s
consumer information booklet [26]. This provides infor-
mation about the NBCSP, including information on
bowel cancer, screening, and completing the FOBT kit.
In the non-tailored PDS arm, participants will not
receive any tailored messages upon completion of the
BS but they will be able to access the NBCSP consumer
information booklet. In the paper-based usual practice
arm, the BS only (without an accompanying consumer
information booklet) will be offered by mail. At that
stage, all participants will be informed that they will
receive an FOBT kit approximately 2 weeks after com-
pletion of the BS. This information will equate to the
‘pre-notification’ process employed in the NBCSP.
All participants who have not opted out of the trial at
the BS phase and have completed a BS will receive a
commonly used FOBT kit of the immunochemical type
(Faecal Immunochemical Test, FIT) that does not
require dietary or drug restrictions, and an invitation to
screen. In the usual practice arm, the offer will consist
of a mailed, personalised (by name and address) invita-
tion to screen and will include printed educational
material in the form of the NBCSP consumer informa-
tion booklet. The offer to PDS participants will parallel
that of the usual practice arm, with the distinction that
the printed educational material will not be provided
but both groups will be reminded that they may return
to the PDS using their supplied username and password
to re-visit messages (tailored arm) and the electronic
version of the NBCSP consumer information booklet. A
reminder will be sent 6 weeks after despatch of FOBT
to those who have not returned their kit.
Participants will be contacted by letter 1-2 weeks after
receipt of their completed FOBT, or 12 weeks following
the invitation to screen for those who haven’tr e t u r n e d
their kit during this period, and requested to complete
an Endpoint Survey (ES) either by returning to the
online site (PDS arms) or completing the accompanying
ES in paper format (usual practice arm). The ES will re-
measure the PHM/PAPM variables included in the BS
and collect additional information relating to the out-
come measures (Table 2).
Qualitative research will be undertaken with a subset
of participants from each arm who will be asked to par-
ticipate in a one-to-one telephone interview. Participants
will be selected with a wide variation in demographic,
psychological and behavioural characteristics (ie we will
seek to interview screening responders and non-respon-
ders). The semi-structured, open-ended interviews will
explore reasons for invitees choosing to engage, or not,
in CRC screening.
Participant follow-up procedures
The study consists of five stages of data collection
(Table 2). All participants will be followed up from
study entry until receipt of the ES, with a sub-set of
those who have completed and not completed an FOBT
being invited to participate in a telephone interview fol-
lowing the ES.
Participant outcome measures
The primary outcomes are (1) return of completed
FOBT within 6 weeks (prior to reminder) and 12 weeks
(after reminder); and (2) change in decision stage on the
PAPM between intention expressed in the BS and deci-
sion stage as measured in the ES. Key secondary out-
comes are (1) change in participant responses to the
PHM variables between completion of the BS and the
ES; (2) decisional conflict and satisfaction scores; and
(3) satisfaction with the screening process. These and
other measures are summarised by collection stage in
Table 2.
Sample size considerations
Randomisation of 3240 participants (1080 in each arm)
takes into consideration predicted attrition of 50% at BS
survey phase, followed by screening offers being distrib-
uted to 1620 survey respondents (540 in each arm).
This permits detection of differential FOBT uptake of at
least 10% between two groups (e.g., 40% vs 50%) with
80% power and alpha of 0.05. To recruit this number of
participants, an initial sample of 18,000 needs to be
approached, given our estimated attrition rates through-
out the study (Figure 1).
Statistical analysis
Primary outcomes
FOBT participation will be compared between arms
using a Chi-squared test. T h ec h a n g ei nc o e f f i c i e n t
method using log binomial generalized linear models
(GLM) will then be used to check for potential covari-
ates (for example, PHM factors, decisional conflict, gen-
der, SES, age band, Internet access characteristics and
so on) and to provide a final adjusted comparison of
screening uptake rates. Change in decision stage will be
analysed using analysis of covariance based on PAPM
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tion having adjusted for the baseline stage.
Secondary outcomes
Changes in participant responses to the PHM variables
will be examined for their relationship to change in
PAPM decision stage and FOBT participation. Log bino-
mial GLMs will be used to determine the best joint pre-
dictors of participation. Scores on decisional conflict
and satisfaction variables will be compared between the
a r m su s i n gac h i - s q u a r e dt e s to rS t u d e n t st - t e s ta s
appropriate. User satisfaction with the screening process
will be assessed by qualitative research; the Framework
analysis approach [27] will be utilised as it is suited to
applied research that incorporates ap r i o r iissues and
that intends to make recommendations for practice.
Content analysis [28] will also be used to identify key
themes and concepts.
Time plan for study
Participant recruitment began in March 2010 and is
planned to continue to July 2010. The final stage of the
study, the qualitative evaluation, is planned to be com-
plete by June 2011. As at September 1
st, N = 3240
(100% of target) had been recruited into the study.
Discussion
The study aims to test the efficacy of the intervention
in participants where the intervention and the screen-
ing process seem feasible. We acknowledge that requir-
ing participants to have access to the Internet may
Table 2 Data collection stages
Phase 1 Eligibility Questionnaire, self-completed on paper. Reminder sent 2 weeks after initial mailing.
Questions addressing the inclusion and exclusion criteria (Additional file 1)
Phase 2.1 Baseline Survey, self-completed on line or on paper as allocated. Reminder sent 2 weeks after initial mailing.
Demographic characteristics
Age, sex, education, country of birth, marital status, employment status
PAPM stage
Decision stage for screening assessed by PAPM stage (never heard of FOBT, aware but not engaged, decided not to act, undecided, decided to
act)
PHM constructs
Scores assessed on salience and coherence, cancer worries, response efficacy, social influence, perceived susceptibility [18]
Self efficacy
Score assessed on confidence to use an FOBT at home
Faecal aversion
Score assessed on distaste or embarrassment toward handling of faeces
Phase 2.2 Invitation to screen, including FOBT. Sent 2-4 weeks after completion of baseline survey with reminder sent 6 weeks after
initial invitation.
Receipt or non-receipt of completed FOBT recorded by the Bowel Health Service (BHS), Repatriation General Hospital
Return of kit
Date of return of kit
Number of participants who contact the ‘help line’ provided as part of the standard BHS protocol
Phase 3.1 Endpoint Survey, self-completed on line or on paper as allocated. Administered 1-2 weeks following receipt of completed
FOBT, or 12 weeks following invitation to screen. Reminder sent 2 weeks after initial mailing.
PAPM stage
PHM construct scores
Self efficacy score
Faecal aversion score
Participation in any other bowel cancer screening activity since entry into trial
Familial history of bowel cancer
Usefulness of the educational material
Satisfaction with content and ease of navigation (PDS arms)
Decisional satisfaction and conflict. Scores assessed by the Decisional Conflict scale [32]
Level of motivation to screen. Scores assessed by the Treatment Self-Regulation Questionnaire [33]
Phase 3.2 Qualitative data, obtained following Endpoint Survey from telephone interviews with a subset of participants in each arm.
Reasons for choosing to participate or not in screening
Usefulness of materials
How the interventions might be improved
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necessary to restrict participants to Internet users to
provide an appropriately controlled evaluation of PDS.
Moreover, we do not consider this restriction will
represent an undesirable degree of selection bias as the
results of an earlier study we conducted found that
more than half the population over 50 years in South
Australia has access to the Internet at some location
[29]. Likewise, participation is limited to those living in
urban postcode regions. This is because those who
have a positive FOBT result will be more likely to
achieve speedy access to gastroenterological services
[30] and incur fewer personal costs and difficulties
[31]. Restriction of study participants to those living in
urban areas will avoid confounding of the results by
service accessibility issues. Once efficacy of the
approach has been established, it will be important to
evaluate effectiveness in the wider at-risk population,
including rural regions, and to identify barriers to its
implementation in those settings.
Additional material
Additional file 1: Study inclusion and exclusion criteria. Details of
participant eligibility criteria
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